-Reuters
Surrozen Initiates Dosing In Phase 1 Clinical Trial Of SZN-043 For Severe Alcoholic Hepatitis
Surrozen, Inc. (“Surrozen” or the “Company”) (NASDAQ:SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration,